These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1985415)

  • 1. An open trial of high-dosage antioxidants in early Parkinson's disease.
    Fahn S
    Am J Clin Nutr; 1991 Jan; 53(1 Suppl):380S-382S. PubMed ID: 1985415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease.
    Fahn S
    Ann Neurol; 1992; 32 Suppl():S128-32. PubMed ID: 1510371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness.
    Fahn S
    Ann N Y Acad Sci; 1989; 570():186-96. PubMed ID: 2698103
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
    Shoulson I
    Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
    Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of deprenyl on the progression of disability in early Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
    McDermott MP; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz CG; Golbe LI; Koller W; Lang AE; Olanow CW
    Arch Neurol; 1995 Jun; 52(6):565-70. PubMed ID: 7763203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: Parkinson's disease and ascorbate.
    Dettman G
    Med J Aust; 1976 Jan; 1(5):131. PubMed ID: 1263962
    [No Abstract]   [Full Text] [Related]  

  • 16. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
    Shults CW; Flint Beal M; Song D; Fontaine D
    Exp Neurol; 2004 Aug; 188(2):491-4. PubMed ID: 15246848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.